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INTRODUCTION
The incidence of anti-erythropoietin (anti-EPO)
antibody-induced pure red cell aplasia (PRCA) in
patients with chronic kidney disease administered
recombinant human erythropoietin (rHuEPO) has been
increasing considerably since 1998 [1]. Although
rHuEPO is identical to endogenous human EPO in its
physicochemical properties, it remains potentially
immunogenic as it is an exogenous protein [2], and it
has been suggested that development of EPO-induced
Characteristic Changes in Anti-erythropoietin
Antibodies in a Peritoneal Dialysis Patient
Who Developed Pure Red Cell Aplasia
Shu-Hong Bi,1,2 Li-Tao Cheng,1 Wei Chen,1,2 Tao Wang1,2
Although cases of anti-erythropoietin (anti-EPO) antibody-induced pure red cell aplasia (PRCA) have been
reported since 1998, the role of anti-EPO antibodies in the development of PRCA is controversial, with
many conflicting opinions. Here, we present a patient who had serial serum anti-EPO antibody levels measured
both before and after the development of PRCA to observe the relationship between serial changes in anti-
EPO antibody and hemoglobin levels. Enzyme-linked immunosorbent assays were used for the detection of
anti-EPO antibodies. The patient’s serum anti-EPO antibody levels showed a characteristic change over
time: negative before the development of PRCA, strongly positive when PRCA was diagnosed, decreasing
after receiving prednisone, and eventually became negative. More importantly, an inversely close association
between changes in serum anti-EPO antibody and hemoglobin levels was shown. The characteristic changes
in this case indicate that anti-EPO antibody might have a role in the development of PRCA, and monitoring
the titer of anti-EPO antibody may be of great value in the diagnosis and treatment of PRCA. [Hong Kong
J Nephrol 2006;8(2):71–4]
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PRCA is related to the presence of anti-EPO antibodies
triggered by the use of rHuEPO [3]. However, recent
cross-sectional studies have shown that some patients
with anti-EPO antibodies do not necessarily develop
PRCA, which cast doubt onto the role of anti-EPO
antibodies in the mechanism of PRCA [4,5]. More
systematic and continuous studies are needed.
Here, we report a patient with PRCA who had
longitudinal follow-up of both anti-EPO antibody and
hemoglobin levels, which demonstrated an inverse
association between changes in anti-EPO antibody and
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hemoglobin levels. The characteristic changes in this
study indicate that anti-EPO antibodies might play a
role in the development of PRCA, and monitoring anti-
EPO antibody titer may be of great value in the
diagnosis and treatment of PRCA.
CASE REPORT
A 77-year-old male was admitted to hospital in August
2003 with the complaints of weakness, easy fatigability
and bad appetite for 4 months. He was diagnosed with
chronic renal failure and put on continuous ambulatory
peritoneal dialysis. He tolerated it well and showed
improvement in his biochemistry and uremic
symptoms. However, as renal anemia persisted
following continuous ambulatory peritoneal dialysis,
epoetin alfa 3,000 U thrice weekly was administered
subcutaneously. The patient recovered well and his
hemoglobin level increased continuously even with
tapered EPO doses. By February 2004, his hemoglobin
had increased to and remained stable at 13.3 g/dL.
In April 2004, however, his hemoglobin level started
to decline without any obvious cause and, 3 months
later, had dropped to 4.4 g/dL. Although increased doses
of epoetin were prescribed, his hemoglobin level
continued to decline and he became severely anemic
and transfusion-dependent (Figure). His hemoglobin
was 4.4 g/dL, hematocrit was 12.6%, mean corpuscular
volume was 93 fL (normal range, 80.2–97.7 fL), and
absolute reticulocyte count was 3.8 × 109/L (0.18%);
white blood cell, platelet and differential white cell
counts were normal. Ilium marrow aspirate showed the
absence of erythroblasts. Megakaryocytes and myeloid
series were normal in morphology and maturation.
Another bone marrow aspirate, but from the sternum,
showed the same results. He had no evidence of
infection, malignancy, hyperparathyroidism, gastro-
intestinal bleeding, hemolysis or iron deficiency, and
serum levels of vitamin B12, folate and ferritin
were normal. His parathyroid hormone level was
37 pg/mL (normal range, 9–55 pg/mL). Antinuclear
antibody, antibody to double-stranded DNA, antibody
to hepatitis C virus and hepatitis B virus surface anti-
gens, antibody to HIV and rapid plasma reagin test
were all negative. X-ray and computed tomography
of the chest did not reveal thymoma. Bone marrow
examination and the clinical picture strongly suggested
PRCA. Therefore, tests for anti-EPO antibodies (from
a fresh sample in June 2004 and a frozen serum sample
from February 2004) were performed using enzyme-
linked immunosorbent assays.
Briefly, the purified known EPO antigens were
diluted to 2 μg/mL in coating buffer (0.05 M bicar-
bonate buffer, pH 9.6) and coated onto the wells of
one half of a Costar microtiter plate (Costar Data
Packaging Corp., Cambridge, MA, USA); the wells in
the other half were coated with coating buffer and acted
as antigen-free wells. The coated plates were incubated
at 37°C for 1 hour, and then washed three times with
phosphate-buffered saline (PBS) containing 0.1%
Tween 20 (PBST) between stages. Test sera were
Figure. There is an inverse association
between change in anti-EPO antibody
titer and change in hemoglobin level
in this EPO-induced PRCA patient.
The broken (dashed) line represents the
standard, normal level of anti-EPO
antibody (23%). The white columns
represent anti-EPO antibody levels.
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Anti-EPO antibody and PRCA
diluted 1:50 with PBST and coated in duplicate on
both antigen-coated wells and antigen-free wells; every
plate contained positive, negative and blank (PBST)
controls. Volumes in the wells at this step and sub-
sequent steps were all 100 μL. Binding was detected
with horseradish peroxidase-conjugated anti-human
IgG (100 μL at 1:2,000 dilution) for 30 minutes at 37°C.
The peroxidase substrate o-phenylenediamine was used
at 0.4 mg/dL in 0.1 M citrate buffer (pH 5.0). The
reaction was stopped by 1 mol/L HCl. Results (reported
in optical density, OD) were recorded as the net OD490nm
(average value on antigen wells minus average value
on antigen-free wells) and expressed as a percentage
according to a linear regression equation established
on the basis of different OD values from a negative
control and a positive control (OD: 1%, 100%
individually). For the control, serum samples from
patients treated with epoetin who did not have PRCA
were tested and an average value of 23% was found.
Titer > 23% was defined as a positive result.
Our patient’s anti-EPO antibody as measured from
the frozen serum sample taken in February 2004 turned
out to be negative, but had changed to be strongly
positive (117%) in June 2004 (Figure). After discussion
between expert nephrologists and hematologists, the
diagnosis of PRCA was made. The administration of
EPO was stopped and a treatment course with oral
prednisone was begun in July 2004 (1 mg/kg daily for
4 weeks, with subsequent tapering of the dose). Eight
weeks after the onset of steroid therapy, the patient’s
serum hemoglobin had stabilized at approximately
8 g/dL without further blood transfusions. His anti-EPO
antibody titer had also decreased substantially to
33.5%, and absolute reticulocyte count had increased
from 3.8 × 109/L (0.18%) to 61.32 × 109/L (2.8%). The
patient continued to respond well to prednisone; by
January 2005, hemoglobin had increased to 10.8 g/dL
and detection of anti-EPO antibody was negative.
DISCUSSION
The major discovery from this case was the inverse
relationship between the changes in anti-EPO antibody
and hemoglobin levels in this EPO-induced PRCA
patient. It is well known that all exogenous proteins,
including therapeut ic  ones,  are  potent ia l ly
immunogenic. Although rHuEPO is identical to
endogenous human EPO with regard to  i ts
physicochemical properties, it remains potentially
immunogenic as it is an exogenous protein [2]. In a
study by Casadevall et al, the identification of anti-EPO
antibodies in 13 patients who had been treated with
EPO and who developed PRCA thereafter suggested
that this recombinant hormone may have played a role
in the etiology of PRCA [3]. Anti-EPO antibodies can
neutralize all EPO molecules in vitro [6], which is
believed to be a major mechanism for inhibiting
erythropoiesis in the body.
However, conflicting reports have emerged in the
literature in recent years, which put the role of anti-
EPO antibodies at the center of the controversy.
Kharagjitsingh et al reported no definite relationship
between anti-EPO antibody and PRCA in their study
[4]. In their anti-EPO antibody screening of the sera of
1,403 dialysis patients on EPO, three patients were
found to have developed anti-EPO antibodies. However,
none of them had a diagnosis of EPO-induced PRCA
and they were all negative for their neutralizing ability.
There was only one PRCA patient found, who was
negative for anti-EPO antibody [4]. This observation
has been supported by other studies [5,7]. These
discrepancies might be related to the different affinities
of the antibodies. It is possible that a patient with a
positive but low affinity anti-EPO antibody will have a
negative neutralizing assay result.
Our patient was diagnosed with EPO-induced
PRCA on the basis of clinical characteristics, bone
marrow examinations and positive detection of anti-
EPO antibody in serum. In addition, other possible
causes of PRCA, such as infections, drugs, autoimmune
disorders, and malignancy, had been excluded. The
highlight of this case is that it presented a characteristic
change in anti-EPO antibody titer and a concomitant
change in serum hemoglobin level. A negative result
for anti-EPO antibody was found in the initial period
of epoetin alfa treatment and the patient responded well
to EPO. After 10 months of EPO administration,
however, anti-EPO antibody became strongly positive
when the patient showed obvious EPO resistance and
progressive decrease in serum hemoglobin. After the
discontinuation of EPO and the onset of steroid therapy,
anti-EPO antibody titers dramatically decreased and
eventually became negative, followed by a gradual
increase in serum hemoglobin. To the best of our
knowledge, this is the first report to show longitudinal
changes in anti-EPO antibody in the course of EPO-
induced PRCA in a dialysis patient. Other than the
inverse association between anti-EPO antibody titer and
hemoglobin level, the start of steroid therapy was
accompanied by a reversal of the trend of increasing
anti-EPO antibody and a noticeable improvement in
anemia independent of transfusion, which further
proved the key role of anti-EPO antibody in the
pathogenesis of EPO-induced PRCA. The efficacy of
the immunosuppressive therapy in this patient’s EPO-
induced PRCA is also in agreement with previous
studies [8–10]. The inverse relationship between the
change in anti-EPO antibody titer and hemoglobin
concentration in this study suggests that anti-EPO
antibody plays a critical role in the pathogenesis of
EPO-induced PRCA.
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In conclusion, this case presented characteristic
changes in serum anti-EPO antibody in a peritoneal
dialysis patient receiving EPO who developed PRCA.
The characteristic changes indicated that anti-EPO
antibody plays a role in the development of PRCA, and
monitoring the titer of anti-EPO antibody may be of
great value in the diagnosis and treatment of PRCA.
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